Research Output per year
The existing business models for antibiotics fail to promote antibiotics stewardship to preserve our existing portfolio of drugs, while at the same time funding for research and development has been insufficient in recent decades, as only two novel classes of antibiotics have been introduced since the 1970s. The UK is considering novel mechanisms for paying for antibiotics to overcome these issues. We will explore the option value for preserving novel antibiotics for extreme events. We will discuss the option value implications for investment in new antibiotics and possible extensions to the model.
|Publication status||Published - 29 Jul 2019|
|Event||INFORMS Healthcare 2019 - Massachusetts Institute of Technology (MIT), Cambridge, United States|
Duration: 26 Jul 2019 → 30 Jul 2019
|Conference||INFORMS Healthcare 2019|
|Period||26/07/19 → 30/07/19|
- healthcare management
- drug investment
Investing in antibiotics to alleviate future catastrophic outcomes: what is the value of having an effective antibiotic to mitigate pandemic influenza?Megiddo, I., Drabik, D., Bedford, T., Morton, A. D., Wesseler, J. & Laxminarayan, R., 1 Apr 2019, In : Health Economics. 28, 4, p. 556-571 16 p.
Research output: Contribution to journal › Article
Activities per year
Itamar Megiddo (Speaker)
9 May 2019
Activity: Talk or presentation types › Invited talk